Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Oncternal Therapeutics In...

    NASDAQ: ONCT · Real-Time Price · USD
    0.53
    -0.16 (-23.63%)
    At close: Dec 02, 2024, 9:00 PM
    -23.63%
    Bid n/a
    Market Cap 1.56M
    Revenue (ttm) 1.67M
    Net Income (ttm) -34.58M
    EPS (ttm) -11.69
    PE Ratio (ttm) -0.04504704875962361
    Forward PE n/a
    Analyst Hold
    Ask n/a
    Volume 644,135
    Avg. Volume (20D) 62,268
    Open 0.70
    Previous Close 0.69
    Day's Range 0.53 - 0.70
    52-Week Range 0.53 - 10.61
    Beta 1.36

    About ONCT

    Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is al...

    [Read more]
    Industry Biotechnology
    Sector Healthcare
    IPO Date Feb 3, 2004
    Employees 27
    Stock Exchange NASDAQ
    Ticker Symbol ONCT
    Website https://www.oncternal.com
    Full Company Profile

    Analyst Forecast

    According to 3 analyst ratings, the average rating for ONCT stock is "Hold." The 12-month stock price forecast is $10, which is an increase of 1798.97% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    5 months ago
    Oncternal Therapeutics shares are trading lowers a... Unlock content with Pro Subscription
    6 months ago
    Octernal Therapeutics shares are trading lower. The company announced updated data from its Phase 1/2 Study of ONCT-534 for the treatment of patients with relapsed or refractory metastatic Castration-Resistant Prostate Cancer.
    news image

    8 months ago · seekingalpha.com

    Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Jim Breitmeyer - President and Chief Executiv...

    news image

    8 months ago · zacks.com

    Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates

    Oncternal Therapeutics (ONCT) came out with a quarterly loss of $2.89 per share versus the Zacks Consensus Estimate of a loss of $3.03. This compares to loss of $3 per share a year ago.

    news image

    11 months ago · seekingalpha.com

    Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q1 2024 Earnings Call Transcript May 9, 2024 5:00 PM ET Company Participants Richard Vincent - CFO Dr. James Breitmeyer - President and CEO Dr. Salim Yazji ...

    news image

    11 months ago · zacks.com

    Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates

    Oncternal Therapeutics (ONCT) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $2.88. This compares to loss of $4 per share a year ago.

    news image

    11 months ago · zacks.com

    All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to Buy

    Oncternal Therapeutics (ONCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    1 year ago · seekingalpha.com

    Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q4 2023 Results Conference Call March 7, 2024 5:00 PM ET Company Participants Richard Vincent - CFO Dr. James Breitmeyer - President and CEO Dr. Salim Yazji...

    news image

    1 year ago · zacks.com

    Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates

    Oncternal Therapeutics (ONCT) came out with a quarterly loss of $3.11 per share versus the Zacks Consensus Estimate of a loss of $3.09. This compares to loss of $4 per share a year ago.

    news image

    1 year ago · seekingalpha.com

    Oncternal Therapeutics, Inc. (ONCT) Q3 2023 Earnings Call Transcript

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Richard Vincent - CFO James Breitmeyer - President and CEO Salim Yazji - C...

    news image

    1 year ago · seekingalpha.com

    Oncternal Therapeutics, Inc. (ONCT) Q2 2023 Earnings Call Transcript

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO C...

    news image

    1 year ago · zacks.com

    Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates

    Oncternal Therapeutics (ONCT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.23 per share a year ago.

    Create Price Alert on ONCT

    Your price alert will notify you when the stock price is above 0.53.

    Add to Watchlist